Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.

Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, Kaehler KC, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D, Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, Löck S, Linn J, Troost EGC, Meier F.

Eur J Cancer. 2019 Mar;110:11-20. doi: 10.1016/j.ejca.2018.12.023. Epub 2019 Feb 7.


Use of complementary and alternative medicine: A multicenter cross-sectional study in 1089 melanoma patients.

Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler KC, Kurschat P, Meiss F, Micke O, Muecke R, Muenstedt K, Stein A, Nashan D, Stoll C, Schmidtmann I, Huebner J.

Eur J Cancer. 2017 Jan;71:70-79. doi: 10.1016/j.ejca.2016.10.029. Epub 2016 Dec 14.


Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.

Kaehler KC, Blome C, Forschner A, Gutzmer R, Haalck T, Heinzerling L, Kornek T, Livingstone E, Loquai C, Maul LV, Lang BM, Schadendorf D, Stade B, Terheyden P, Utikal J, Wagner T, Hauschild A, Garbe C, Augustin M.

Medicine (Baltimore). 2016 Nov;95(46):e5375.


Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma.

Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler KC, Kurschat P, Meiss F, Stein A, Nashan D, Micke O, Muecke R, Muenstedt K, Stoll C, Schmidtmann I, Huebner J.

Med Oncol. 2016 May;33(5):52. doi: 10.1007/s12032-016-0764-6. Epub 2016 Apr 18.


Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA.

Science. 2015 Oct 9;350(6257):207-211. doi: 10.1126/science.aad0095. Epub 2015 Sep 10. Erratum in: Science. 2015 Nov 13;350(6262):aad8366. Science. 2016 Apr 15;352(6283). pii: aaf8264. doi: 10.1126/science.aaf8264.


Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays.

Kaehler KC, Politz O, Henderson D, Ulbrich HF, Hauschild A, Mund C, Egberts F.

Melanoma Res. 2015 Jun;25(3):225-31. doi: 10.1097/CMR.0000000000000150.


Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.

Kaehler KC, Gutzmer R, Egberts F, Hauschild A.

J Dtsch Dermatol Ges. 2014 Oct;12(10):906-7. doi: 10.1111/ddg.12342. Epub 2014 Jul 17. No abstract available.


Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.

Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R; Dermatology Cooperative Oncology Group (DeCOG).

Eur J Cancer. 2014 Jan;50(2):406-10. doi: 10.1016/j.ejca.2013.09.014. Epub 2013 Oct 29.


The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.

Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM.

PLoS One. 2013;8(1):e53745. doi: 10.1371/journal.pone.0053745. Epub 2013 Jan 14.


Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM.

Egberts F, Hartje C, Schafmayer C, Kaehler KC, von Schönfels W, Hauschild A, Becker T, Egberts JH.

Ann R Coll Surg Engl. 2011 Oct;93(7):514-22. doi: 10.1308/147870811X13137608455019.


Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.

Egberts F, Gutzmer R, Ugurel S, Becker JC, Trefzer U, Degen A, Schenck F, Frey L, Wilhelm T, Hassel JC, Schadendorf D, Livingstone E, Mauch C, Garbe C, Berking C, Rass K, Mohr P, Kaehler KC, Weichenthal M, Hauschild A.

Ann Oncol. 2011 Jul;22(7):1667-74. doi: 10.1093/annonc/mdq648. Epub 2011 Jan 10.


Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.

Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D.

Semin Oncol. 2010 Oct;37(5):485-98. doi: 10.1053/j.seminoncol.2010.09.003. Review. Erratum in: Semin Oncol. 2012 Oct;39(5):625.


Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.

Egberts F, Momkvist A, Egberts JH, Kaehler KC, Hauschild A.

Anticancer Res. 2010 May;30(5):1799-805.


Electrochemotherapy in symptomatic melanoma skin metastases: intraindividual comparison with conventional surgery.

Kaehler KC, Egberts F, Hauschild A.

Dermatol Surg. 2010 Jul;36(7):1200-2. doi: 10.1111/j.1524-4725.2010.01608.x. Epub 2010 Jun 1. No abstract available.


Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma >or=1 mm.

Egberts F, Momkvist A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A.

Tumour Biol. 2010 Jan;31(1):8-15. doi: 10.1007/s13277-009-0002-3. Epub 2009 Dec 18.


Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.

Kaehler KC, Sondak VK, Schadendorf D, Hauschild A.

Eur J Cancer. 2010 Jan;46(1):41-6. doi: 10.1016/j.ejca.2009.10.004. Review.


Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.

Kaehler KC, Egberts F, Lorigan P, Hauschild A.

Melanoma Res. 2009 Oct;19(5):333-4. doi: 10.1097/CMR.0b013e32832e0bff.


Melanocytic schwannoma of the cutaneous and subcutaneous tissues: three cases and a review of the literature.

Kaehler KC, Russo PA, Katenkamp D, Kreusch T, Neuber K, Schwarz T, Hauschild A.

Melanoma Res. 2008 Dec;18(6):438-42. doi: 10.1097/CMR.0b013e32831270d7. Review.


Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.

Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D.

Melanoma Res. 2008 Aug;18(4):274-8. doi: 10.1097/CMR.0b013e328307c248.


Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.

Hauschild A, Dummer R, Ugurel S, Kaehler KC, Egberts F, Fink W, Both-Skalsky J, Laetsch B, Schadendorf D.

Cancer. 2008 Sep 15;113(6):1404-11. doi: 10.1002/cncr.23722.


Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.

Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A.

Onkologie. 2008 Jul;31(7):380-4. doi: 10.1159/000135492. Epub 2008 Jun 18.


Metastatic melanoma of the tongue arising from oral melanosis.

Kaehler KC, Russo PA, Egberts F, Warnke PH, Cerroni L, Hauschild A.

Arch Dermatol. 2008 Apr;144(4):558-60. doi: 10.1001/archderm.144.4.558-b. No abstract available.


Multiple skin metastases of malignant melanoma with unusual clinical and histopathologic features in an immunosuppressed patient.

Egberts F, Kaehler KC, Brasch J, Schwarz T, Cerroni L, Hauschild A.

J Am Acad Dermatol. 2008 May;58(5):880-4. doi: 10.1016/j.jaad.2007.12.028. Epub 2008 Feb 6.


An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma.

Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V, Skalsky J, Kaehler KC, Moosbauer S, Clark R, Meng TC, Urosevic M.

Clin Cancer Res. 2008 Feb 1;14(3):856-64. doi: 10.1158/1078-0432.CCR-07-1938.


Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).

Spieth K, Kaufmann R, Dummer R, Garbe C, Becker JC, Hauschild A, Tilgen W, Ugurel S, Beyeler M, Bröcker EB, Kaehler KC, Pföhler C, Gille J, Leiter U, Schadendorf D.

Ann Oncol. 2008 Apr;19(4):801-6. doi: 10.1093/annonc/mdm565. Epub 2008 Jan 4.


Giant naevoid syringocystadenoma papilliferum.

Kaehler KC, Lange-Asschenfeldt B, Proksch E, Hauschild A.

Acta Derm Venereol. 2005;85(5):453-4. No abstract available.

Supplemental Content

Loading ...
Support Center